FDA-Approved Drug for Treatment of Actinic Keratosis (AK)
The University of Chicago and Dr. Tsoukas are conducting a study to compare the treatment of skin growths called actinic keratosis (AK) with 5-ALA PDT versus treatment with other conventionally used drugs such as cryotherapy, Imiquimod, or 5-fluorouracil (5-FU). All drugs used in this study are approved by the Food and Drug Administration (FDA) for use in patients with AK.
After you are screened for study participation, you will undergo the 5-ALA PDT treatment during which a clear solution will be applied to one part of your body and then exposed to a special type of light. During conventional therapy the other part of your body will be treated either with cold spray (cryotherapy) or a cream called Imiquimod or a cream called 5-FU. You will be given the option as to whether you would like to apply 5-FU, Imiquimod or be treated with cryotherapy on that side. You will be asked to apply only one of these three conventional treatment and a record as to which of these three conventional treatments was used will be kept by Dr. Tsoukas. This research is being conducted because currently there is no data to support which of these treatments is more effective for the treatment and prevention of a recurrence of AK.
Your may participate in this study for up to 18 months.
There may or may not be a direct medical benefit to you as a result of taking part in this study. Information from this study may help in the treatment of actinic keratosis. This information will add to the medical knowledge of how to diagnose, monitor, or treat people with actinic keratosis in the future.
Participation Details
Initial selection criteria include:
- Must be at least 18 years of age
- Must have actinic keratosis
- Must be available for clinic visits for the duration of the study
- Must meet study medical criteria as evaluated by Dr. Tsoukas
Study Director: Maria Tsoukas, MD
Department: Medicine, Section of Dermatology
For more information contact:
1-866-9UC-DERM
IRB: #15725A
